What are the risks of Quercetin?

Safety Profile Quercetin at typical dietary and supplemental doses has an excellent safety profile. Multiple Phase I and Phase II clinical trials have evaluated doses up to 2,000mg/day for periods of weeks to months without identifying serious safety signals. Common Adverse Effects At doses above 1g

How long does Quercetin last?

The total duration of Quercetin via oral is 6 hours to 12 hours.

Quercetin — SubstanceWiki

Quercetin

Flavonol, Flavonoid, Polyphenol · Senolytic, Anti-inflammatory, Neuroprotective

Senolytic, Anti-inflammatory, Neuroprotective(Flavonol, Flavonoid, Polyphenol)

Quick Dosage

Oral500–1000 mg (common)

Total duration (Oral)6hr–12hr

View full details

Quercetin is a flavonol — a subclass of the flavonoid polyphenols — found abundantly in onions (among the richest dietary sources), apples, capers, berries, grapes, tea, and many other plant foods. It is the most widely distributed flavonoid in the human diet and has been extensively studied for anti-inflammatory, antioxidant, cardiovascular, antiviral, and, more recently, senolytic properties.

Quercetin's mechanistic profile is broad and multi-targeted. At standard dietary and supplemental doses, it primarily functions as an anti-inflammatory agent (inhibiting multiple inflammatory signaling pathways), antioxidant (direct radical scavenging and indirect Nrf2 activation), and antihistamine (inhibiting histamine release from mast cells — the basis for its use in allergy contexts). At higher doses studied in the senolytic research literature, quercetin (typically combined with the BCL-2 inhibitor dasatinib) demonstrates the capacity to selectively eliminate senescent cells — damaged, non-dividing cells that accumulate with aging, resist apoptosis, and secrete a pro-inflammatory mixture of cytokines (the "SASP," senescence-associated secretory phenotype) that drives many hallmarks of aging.

The senolytic application is perhaps the most scientifically significant recent development in the quercetin literature. The Mayo Clinic group led by James Kirkland published a series of papers beginning in 2015 demonstrating that quercetin combined with dasatinib eliminated senescent cells in mice, reversed multiple aging-related dysfunctions, and extended healthspan. In 2019, the first human clinical trial of dasatinib + quercetin as a senolytic published in EBioMedicine showed reduced senescent cell burden and reduction of multiple inflammatory and senescence biomarkers in patients with idiopathic pulmonary fibrosis. Subsequent trials have examined this combination in other aging-related conditions.

Like many polyphenols, quercetin has poor oral bioavailability — approximately 1–3% of parent compound reaches systemic circulation. Quercetin glucosides (present in foods) are better absorbed than quercetin aglycone; quercetin phytosome formulations and encapsulated forms substantially improve bioavailability.

Pharmacology

Anti-Inflammatory Mechanisms

Quercetin is a potent inhibitor of multiple inflammatory signaling pathways:

NF-κB inhibition: Quercetin inhibits IKK (IκB kinase), blocking NF-κB translocation to the nucleus and suppressing transcription of TNF-α, IL-1β, IL-6, COX-2, and iNOS
MAPK pathway inhibition: Suppresses JNK and p38 MAPK signaling, reducing inflammatory gene expression
Inflammasome inhibition: Inhibits NLRP3 inflammasome assembly and activation, reducing IL-1β and IL-18 maturation
Mast cell stabilization: Inhibits IgE-mediated mast cell degranulation, reducing histamine, prostaglandin D2, and leukotriene release — the mechanism for quercetin's antiallergic effects
COX and LOX inhibition: Direct inhibition of cyclooxygenase and lipoxygenase enzymes, reducing prostaglandin and leukotriene synthesis

Senolytic Mechanism

Senescent cells resist apoptosis through upregulation of multiple pro-survival ("senescent cell anti-apoptotic pathways," SCAPs) including Bcl-2 family proteins, PI3K/AKT, and other pathways. Quercetin inhibits several of these survival pathways:

Bcl-2 and Bcl-xL inhibition: Quercetin is a BH3 mimetic, binding to and inhibiting the anti-apoptotic Bcl-2 family proteins that senescent cells depend on for survival
PI3K inhibition: Quercetin inhibits PI3K pathway signaling, reducing AKT-mediated pro-survival signaling
Ephrin pathway inhibition: Blocks survival signals via ephrin receptors

In combination with dasatinib (which inhibits additional survival tyrosine kinases), quercetin produces synergistic senolytic activity that efficiently eliminates senescent cells while sparing healthy proliferating and quiescent cells. Importantly, senolytic dosing is typically intermittent (e.g., two consecutive days per month rather than daily), as a "hit-and-run" strategy — clearing accumulated senescent cells and then pausing to allow recovery.

CD38 Inhibition

Like apigenin, quercetin inhibits CD38 — the NAD+-consuming enzyme — and has been shown to increase intracellular NAD+ levels in preclinical models. This positions quercetin as a complementary compound to NAD+ precursor supplementation.

Antioxidant Mechanisms

Direct free radical scavenging: Multiple phenolic OH groups donate hydrogen to neutralize ROS
Metal chelation: Quercetin chelates iron and copper, reducing Fenton reaction-mediated hydroxyl radical generation
Nrf2 activation: Indirect antioxidant effects via ARE gene induction (modest compared to sulforaphane)

Antiviral Properties

Quercetin inhibits viral entry and replication through multiple mechanisms, including inhibition of viral proteases, viral polymerases, and interference with viral receptor binding. It has demonstrated activity against influenza, SARS-CoV-2, Zika, and other viruses in cell culture and animal models, generating substantial interest during the COVID-19 pandemic.

Pharmacokinetics

Oral bioavailability of quercetin aglycone is approximately 1–3%. Quercetin glucosides (quercetin-3-glucoside from onions, rutin/quercetin-3-glucoside from buckwheat) are better absorbed via active sugar transporter mechanisms. Following absorption, quercetin is rapidly metabolized to phenolic acid metabolites and sulfate/glucuronide conjugates. The bioactive entity in plasma is primarily conjugated metabolites, not parent quercetin. Quercetin phytosome formulations achieve 20-fold improved bioavailability.

History

Early Flavonoid Research

Quercetin's scientific history begins with the broader story of flavonoid chemistry. In the 1930s, Hungarian-American biochemist Albert Szent-Györgyi (who had recently won the Nobel Prize for the discovery of vitamin C) proposed that a class of plant compounds he called "vitamin P" — which included flavonoids now identified as quercetin, rutin, and hesperidin — had vitamin-like activity in preventing capillary fragility. The "vitamin P" hypothesis was eventually discarded as flavonoids were not found to be essential nutrients in the classical sense, but the research generated early characterization of quercetin's chemical properties and biological effects.

Quercetin was first isolated in the mid-19th century from oak bark (Quercus species — the genus name is the etymological root of "quercetin"). The structure was characterized in the early 20th century, and the compound was recognized as one of the most widely distributed flavonoids in the plant kingdom.

Rise as a Research Subject

Quercetin attracted sustained research attention through the latter 20th century as the epidemiological association between dietary flavonoid intake and reduced cardiovascular disease and cancer risk drove interest in identifying the responsible phytochemicals. Quercetin, as the most abundant dietary flavonoid, became a primary research target.

Mechanistic research through the 1990s and 2000s characterized its NF-κB inhibitory, antioxidant, antihistaminic, and antiproliferative properties, generating thousands of published studies — though many relied on cell culture concentrations not achievable with oral supplementation.

Senolytic Discovery

The most significant recent development in quercetin research is its identification as a senolytic compound. This emerged from a systematic screen conducted at the Mayo Clinic by Kirkland, Tchkonia, and colleagues, published in Aging Cell in 2015, identifying quercetin (in combination with dasatinib) as one of the first compounds capable of selectively eliminating senescent cells in living organisms. The subsequent demonstration of improved physical function, reduced mortality, and extended healthspan in mice treated with senolytic quercetin + dasatinib, and the publication of the first human senolytic trial in 2019, have placed quercetin at the center of one of the most exciting areas of aging biology research.

Full	Unknown
Half	Unknown
Zero	Unknown

Quercetin

Quick Dosage

Dosage

Oral

Duration

Subjective Effects

Physical Effects

Physical(2)

Pharmacology

Anti-Inflammatory Mechanisms

Senolytic Mechanism

CD38 Inhibition

Antioxidant Mechanisms

Antiviral Properties

Pharmacokinetics

Interactions

History

Early Flavonoid Research

Rise as a Research Subject

Senolytic Discovery

Harm Reduction

Bioavailability-Enhanced Formulations for Systemic Effects

Senolytic Dosing Protocol (If Pursuing This Application)

Standard Supplemental Dosing (Anti-inflammatory, NAD+, Antioxidant)

Drug Interactions

Toxicity & Safety

Safety Profile

Common Adverse Effects

Potential Nephrotoxicity at Very High Doses

Drug Interactions

Pregnancy

Addiction Potential

Tolerance

Legal Status

Tips (3)

References (4)

Frequently Asked Questions